Inhibiting CAF has been recognized as a therapeutic strategy, and targeting FAP has shown promise in controlling tumor progression in preclinical models (Brennen et al., 2012[8]; Kakarla et al., 2013[49]). This evidence concerns the gene FAP and neoplasm.